Impella Saves Live in CS, but Patient Selection Key
In the first randomized trial of Impella in a select group of patients with AMI and cardiogenic shock, the device saved lives. The high rate of serious adverse events calls us to pay attention to the nuances of the data, says John Mandrola, MD.